文章：

重组病毒与其他抗癌疗法：溶瘤病毒疗法的进步

Recombinant viruses with other anti-cancer therapeutics: a step towards advancement of oncolytic virotherapy 

原文发布日期：2018-05-08 

英文摘要：

Cancer as a disease is a multifaceted foe which sometimes succumbs to the prescribed treatment and sometimes develops resistance against various therapies. Conventional cancer therapies suffer from many limitations, the least of which is their specificity and systemic side effects. In a majority of cases, acquired mutations render the cancer cells resistant to therapy and lower the prognostic outcome. In the constant effort to devise a therapeutic moiety which can comprehensively eliminate cancer cells, oncolytic viruses provide an attractive avenue as they selectively infect and lyse cancer cells sparing normal cells from their effects. Viruses can be engineered for their host specificity and toxicity as a promising anti-cancer tool. As it is essential to devise a strategy to address all targets involved in cancer development and progression, the idea of using oncolytic viruses with enhanced anti-cancer activity through arming with foreign genes gained merit and is showing promising advent in clinical studies. The use of oncolytic viruses as an agent of combination therapy for cancer treatment also gained much attention in the recent past. This review focuses on the emerging role of oncolytic viruses as vital components of anti-cancer regimen presenting a new dimension in an ever-changing cancer therapy scenario. 

摘要翻译：

癌症是一种多面性的敌人，有时会屈服于既定治疗，有时却对多种疗法产生耐药性。传统癌症疗法存在诸多局限性，其中特异性和全身性副作用只是冰山一角。在多数情况下，获得性突变会使癌细胞产生治疗耐受性，导致预后恶化。在持续探索能全面清除癌细胞的治疗策略过程中，溶瘤病毒因其能选择性感染并裂解癌细胞，同时避免损伤正常细胞的特点，提供了极具吸引力的治疗途径。通过基因工程技术可改造病毒的宿主特异性和毒性，使其成为有前景的抗癌工具。鉴于制定针对癌症发生发展所有相关靶点的策略至关重要，通过外源基因武装增强溶瘤病毒抗癌活性的理念已获得认可，并在临床研究中展现出良好前景。近年来，溶瘤病毒作为联合治疗剂应用于癌症治疗也备受关注。本综述重点探讨溶瘤病毒在抗癌方案中日益重要的新兴角色，为不断演变的癌症治疗格局带来新维度。

原文链接：

Recombinant viruses with other anti-cancer therapeutics: a step towards advancement of oncolytic virotherapy